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bjectives The E-Five registry was designed to evaluate the safety and effectiveness of the En-
eavor zotarolimus-eluting stent (ZES) (Medtronic CardioVascular, Santa Rosa, California) for the
reatment of coronary artery stenosis across a wide range of patients treated in real-world clinical
ractice settings.
ackground Early clinical trials with the Endeavor ZES have demonstrated low rates of target lesion
evascularization with a favorable safety proﬁle including low late stent thrombosis with up to 4
ears of follow-up. A clinical registry was designed to complement controlled trial data by examin-
ng a large patient population, including high-risk patient subsets.
ethods The E-Five registry is a prospective, nonrandomized, multicenter global registry conducted
t 188 centers worldwide. Adult patients (n  8,314) with coronary artery disease who underwent
ingle-vessel or multivessel percutaneous coronary intervention were enrolled. The primary end
oint was the rate of major adverse cardiac events (MACE) at 12 months. A secondary analysis strat-
ﬁed patients by standard versus extended-use clinical and lesion characteristics.
esults Overall 12-month outcome rates were MACE 7.5%; cardiac death 1.7%; myocardial infarc-
ion (all) 1.6%; target lesion revascularization 4.5%; and stent thrombosis (Academic Research Con-
ortium deﬁnite and probable) 1.1%. The 12-month MACE rates were 4.3% and 8.6% for standard-
nd extended-use patients, respectively (p  0.001).
onclusions This large, international multicenter registry provides important information regarding
he long-term safety and efﬁcacy of the Endeavor ZES across standard and extended-use patients in
he real-world setting. Rates of MACE and measures of safety including cardiac death, myocardial
nfarction, and stent thrombosis were low and consistent with pooled results of clinical trials.
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1228esults from multiple randomized trials demonstrate that
rug-eluting stents (DES) significantly reduce rates of
estenosis and target lesion revascularization (TLR) in
atients with symptomatic coronary artery disease when
ompared with bare-metal stents (BMS) (1–4). Although
oncerns have been raised about the safety of DES due to
See page 1236
pparent increases in late stent thrombosis, the clinical
enefits seem to outweigh the risks (5). Experience with
ES now extends to patients outside of controlled clinical
rials, allowing for the inclusion of patients with diverse
characteristics and more com-
plex clinical or angiographic pre-
sentations, such as diabetes,
multivessel disease, acute myo-
cardial infarction (MI), or long
lesions, as is often seen in real-
world practice settings.
Clinical registries are excellent
complements to randomized
controlled studies because they
provide insight into the perfor-
mance of DES in broader pa-
tient populations as well as spe-
cial patient subsets. The E-Five
registry is a prospective, nonran-
domized, multicenter global reg-
istry conducted at 188 centers in
Europe, Asia/Pacific, and Latin
America designed to evaluate the
safety and effectiveness of the En-
deavor zotarolimus-eluting stent
(ZES) (Medtronic CardioVascu-
lar, Santa Rosa, California) in
routine treatment of patients with
coronary artery stenosis, including
patients with clinical characteris-
tics or lesion types that are often
excluded from randomized con-
rolled trials (6). The registry includes over 8,000 adult patients
ho underwent single-vessel or multivessel percutaneous cor-
nary intervention (PCI). The primary end point was the rate
f major adverse cardiac events (MACE) at 12 months (6).
The Endeavor ZES received Conformité Européenne (CE)
arking in August 2005 and U.S. Food and Drug Adminis-
ration approval in February 2008. The safety and efficacy of
he Endeavor ZES has been evaluated in a number of clinical
rials, and the results consistently show low rates of angio-
raphic restenosis and repeat revascularization as well as a
avorable safety profile, with a low rate of late stent thrombosis
bbreviations and
cronyms
RC  Academic Research
onsortium
MS  bare-metal stent(s)
EC  clinical events
ommittee
K-MB  creatine kinase-
yocardial band
ES  drug-eluting stent(s)
ACE  major adverse
ardiac events
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularization
VF  target vessel failure
VR  target vessel
evascularization
ES  zotarolimus-eluting
tent(s)eyond 12 months of follow-up (4,7–12). TPreliminary 30-day data for 1,989 patients enrolled in the
-Five registry were published in 2007 (6). The acute
rocedure success rate was 98.6%, which is comparable with
rocedure success rates observed in previous Endeavor ZES
linical trials. The 30-day rate of MACE in these patients
as 1.7%, which is also comparable with 30-day rates of
ACE observed in previous Endeavor clinical trials.
This report describes 12-month safety and clinical data
rom the E-Five registry for all patients in the registry and
urther examines the outcomes among patients with clinical
nd lesion characteristics similar to those enrolled in ran-
omized clinical trials (standard-use group) compared with
atients with more complex clinical (e.g., acute MI) and
esion (e.g., bifurcation, left main) characteristics (extended-
se group) (Fig. 1).
ethods
tudy design and objectives. The E-Five registry is a
rospective, nonrandomized, multicenter registry conducted
t 188 centers in Europe, Asia/Pacific, and Latin America.
he registry includes 8,314 adult patients who underwent
ingle-vessel or multivessel PCI. The primary objective of
he E-Five registry was to evaluate the safety and overall
linical performance of the Endeavor ZES (Medtronic
ardioVascular) in real-world patients who required stent
mplantation. The secondary objective was to assess the
vent rate in patient subgroups known to have a higher risk
f MACE, such as those with diabetes mellitus, small
essels, and long lesions.
tudy population and protocol. All patients with coronary
rtery lesions suitable for stenting were eligible for recruit-
ent in the registry. Consecutive patients for whom im-
lantation with an Endeavor ZES was intended were
nrolled at the time of stent introduction into the guiding
atheter. The registry population included a large number of
atients with clinical and lesion characteristics that did not
t the standard-use criteria of previous clinical trials and
hus are included in an extended-use group. The extended-
se group was defined as patients with a baseline acute MI
within 72 h), left main stenting, saphenous vein grafts,
n-stent restenosis, bifurcated or ostial lesions, severe tortu-
sity, multivessel stenting, moderate/severe calcification,
eference vessel diameter 2.5 mm or 3.5 mm, lesion
ength 27 mm, or moderate or severe renal impairment.
ll other patients were classified as standard use.
Patients were permitted to have 1 or more Endeavor ZES
mplanted, and implantation of BMS or other DES was
llowed if the investigators deemed it beneficial.
Before stent implantation, all patients received daily
spirin per their physician’s usual practice and either clopi-
ogrel 75 mg/day for 3 days before the procedure or a
reprocedural loading dose of clopidogrel (at least 300 mg).
he recommended maintenance regimen was clopidogrel
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12295 mg/day for at least 12 weeks and at least 75 mg/day of
spirin indefinitely. Glycoprotein IIb/IIIa inhibitors were
llowed at physician discretion.
Clinical follow-up was scheduled at 30 days, 6 months,
nd 12 months and consisted of telephone or in-office
ssessments. Patients were followed for 12 months to
etermine the mid-term clinical outcome of the index
rocedure.
This study was conducted according to the Declaration of
elsinki. The medical ethics committees approved the
tudy protocol at sites at which such approval was required.
n other cases, the medical ethics committees were notified
f the study or investigators signed a statement before
atient enrollment confirming that neither approval by nor
otification of their ethics committees was necessary and
hat this approach was in accordance with local regulations.
ritten informed consent was obtained from all patients.
evice description. There are 3 main components of the
ndeavor ZES: 1) the cobalt alloy stent; 2) zotarolimus (10
g/mm stent length), an antiproliferative drug that is a
ynthetic analog of sirolimus and has a similar mechanism of
ction; and 3) a proprietary biomimetic phosphorylcholine
olymer coating. The Endeavor ZES is available in dia-
eters of 2.25 to 4.0 mm and in lengths of 8 to 30 mm.
ata collection and management. Data were recorded on
eb-based electronic case report forms. For quality control
urposes, clinical sites were randomly monitored, and 10%
f the data was monitored.
The following data were collected at baseline: eligibility
riteria, demographic data, cardiac risk factors, current
ardiac status, lesion characteristics, and results from pre-
Standard Use
2125/8314 = 
25.6%
Extended Use 
6189/8314 = 74.4%
Figure 1. Patient and Lesion Characteristics of Extended-Use Group Patien
Distribution and speciﬁc characteristics deﬁning the extended-use group are s
myocardial infarction; RVD  reference vessel diameter.rocedure angiography. Visual estimation of lesion charac- geristics in relation to the index procedure was performed by
he operator and recorded. Cardiac enzymes were measured
fter the procedure according to local hospital practice,
ncluding measurement of creatine kinase (CK), creatine
inase-myocardial band (CK-MB), and troponin.
Data on the index procedure, including the number of
esions treated, devices used, and the implantation tech-
ique, were recorded as well as the angiographic outcome
visual), antiplatelet medications used, MACE, and electro-
ardiography results. During discharge and after 30 days, 6
onths, and 12 months, current cardiac status, antiplatelet
edications, and MACE events were recorded. If a non–
-wave or Q-wave myocardial infarction (MI) occurred
fter PCI, peak CK and CK-MB values were collected for
djudication by the clinical events committee (CEC). After
ll ischemic or MACE events, angiographic results and
lectrocardiograms were collected.
There was no mandatory angiographic follow-up in the
rotocol; however, if a patient had angiography for revas-
ularization, the angiogram was reviewed by a central CEC
Cardialysis, Rotterdam, the Netherlands). The CEC, con-
isting of independent cardiologists who were not investi-
ators in the registry, was responsible for adjudicating all
eported MACE and stent thrombosis events and classify-
ng the events according to the protocol definitions and, for
tent thrombosis, the Academic Research Consortium
ARC) definitions (13).
tudy end points. The primary end point of the E-Five
egistry was the rate of MACE at 12 months. For this study,
e defined MACE as the composite end point of death, MI
Q-wave and non–Q-wave), emergent cardiac bypass sur-
• AMI (<72 hrs)                           13.9%
• Multivessel stenting 10.9%
• Long lesion (>27 mm)             16.6%
• Ostial lesion                               5.8%
• Bifurcated lesion                      18.9%
• In-stent restenosis 4.8%
• Graft stenting 1.8%
• Severe tortuosity 3.3%
• Small or large vessel               18.3%
(RVD<2.5 mm or >3.5 mm)
• Left main stenting 2.4%
• Moderate/severe 
calcification                             31.6%
• Moderate/severe renal           
impairment                                5.3%
(right). All other patients made up the standard-use group. AMI  acutets
hownery, or TLR (repeat percutaneous transluminal coronary
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1230ngioplasty or coronary artery bypass graft). Non–Q-wave
I was defined as elevated CK 2 the upper limit of
ormal with the presence of elevated CK-MB in the
bsence of new pathologic Q waves.
Secondary end points were the rates of MACE at 30 days
nd 6 months; the per protocol stent thrombosis rate (early
efined as 0 to 30 days; late defined as 31 to 360 days); the
rocedural success rate; device success rate; and lesion
uccess rate. Per-protocol stent thrombosis was defined as
ocumented ischemia with angiographic thrombus within
he stented vessel at any time or any death attributed to a
ardiac cause within the first 30 days in the absence of
ngiographic confirmation. The ARC-defined definite and
robable stent thrombosis rates (early and late) were also
nalyzed.
tatistical analyses. With an estimated event rate for
ACE at 12 months of approximately 11% and with an
ssumed loss to follow-up rate of 10%, a sample size of
,000 patients was needed so that the 95% confidence
nterval of MACE at 12 months would not exceed 11.7%.
The primary analytical population consisted of all en-
olled patients in whom an Endeavor stent was attempted
nd/or implanted. A secondary analysis compared outcomes
n the extended-use and standard patient subgroups.
The baseline demographic and lesion characteristics,
rocedural characteristics, and the clinical outcomes were
stimated and reported for overall population and then for
he 2 subgroups. Categorical variables were reported with
ercentages and counts, and continuous variables were
eported with the means and standard deviations. The time
Table 1. Patient Characteristics and Demographic Data
Overall
(n  8,314)
Age, yrs 63.3 11.1
Female 23.3 (1,940)
Prior MI 32.2 (2,673)
Prior PCI 25.3 (2,106)
Prior CABG 7.5 (627)
Hypertension 68.6 (5,704)
Hypercholesterolemia 63.1 (5,243)
Current smoker 22.6 (1,882)
Diabetes 32.7 (2,721)
Insulin-dependent 8.2 (682)
Noninsulin-dependent 24.5 (2,039)
Acute coronary syndrome 47.8 (3,973)
Acute MI (72 h) 13.9 (1,153)
Unstable angina 33.9 (2,820)
Moderate renal impairment (serum creatinine 140–220 mol/l) 4.7 (317/6,72
Severe renal impairment (serum creatinine 220 mol/l) 1.8 (120/6,720
Values are mean  SD or % (n). *Standard-use excludes patients with baseline acute myocardial i
tortuosity, multivessel stenting, moderate/severe calcification, reference vessel diameter 2.5 m
†Extended-use includes all other patients.CABG coronary artery bypass grafting; PCI percutaneous coronary intervention.o MACE event, stent thrombosis, and TLR were summa-
ized and displayed with cumulative incidence curves by
aplan-Meier methods.
Extended- and standard-use subgroups were compared
or baseline characteristics and clinical outcomes. The p
alues were calculated with a 2-sample t test for continuous
ariables or Fisher exact test for categorical variables.
esults
atient demographic data and characteristics. In total,
,314 patients were recruited to the E-Five registry at
88 sites worldwide. Twelve-month data were available
or 7,832 (94.2%) of the 8,314 patients enrolled. The
ean age was 63.3  11.1 years, and 76.7% of patients
ere men (Table 1). The incidence of diabetes was
2.7%, acute coronary syndrome occurred in 47.8% of
atients, and moderate-to-severe renal impairment was
eported in 6.5% of patients (Table 1). The population
ncluded patients with clinical risk factors and lesion
haracteristics not typically studied in randomized clini-
al trials (Table 2). The extended-use group comprised
,189 (74.4%) patients (Fig. 1).
esion and procedural characteristics. Lesion and procedural
haracteristics are reported in Table 2. The average lesion
ength was 18.5 10.6 mm. On average, the number of stents
mplanted/patient was 1.47. In total, 28.6% of lesions were
reated with small stents (2.5 mm in diameter). The average
tent length was 23.5 12.2 mm, and the stent-to-lesion ratio
Standard-Use*
(n  2,125)
Extended-Use†
(n  6,189)
p Value
(Standard- vs. Extended-Use)
61.3 10.6 64.0 11.1 0.001
24.8 (527) 22.8 (1,413) 0.065
29.9 (636) 32.9 (2,037) 0.011
22.7 (482) 26.2 (1,624) 0.001
4.9 (104) 8.5 (523) 0.001
67.1 (1,426) 69.1 (4,278) 0.088
62.2 (1,321) 63.4 (3,922) 0.322
22.7 (483) 22.6 (1,399) 0.904
31.1 (661) 33.3 (2,060) 0.068
7.0 (149) 8.6 (533) 0.022
24.1 (512) 24.7 (1,527) 0.599
N/A 50.0 (3,093) —
N/A 18.6 (1,153) —
41.4 (880) 31.3 (1,940) 0.001
N/A 6.3% (317/5,094) —
N/A 2.4% (120/5,094) —
n (MI) (within 72 h), left main, saphenous vein graft, in-stent restenosis, bifurcation, ostial, severe
rence vessel diameter 3.5 mm, lesion length 27 mm, moderate or severe renal impairment.0)
)
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1231as 1.4  0.7 mm. The Endeavor ZES was the only stent
mplanted in 94.9% of lesions. Other patients received a BMS
2.1%) or another DES (2.7%) or both (0.3%) in addition to
he Endeavor ZES. The overall lesion success rate was 99.7%,
nd the overall procedure success rate was 98.6%.
ntiplatelet therapy. At baseline, periprocedure, 90.4% of
atients were taking aspirin plus clopidogrel or ticlopidine,
.9% were taking clopidogrel or ticlopidine alone, 6.1%
ere taking aspirin alone, and 1.6% of patients were not
aking any antiplatelet therapy. The percentage of patients
aking dual antiplatelet therapy was 97.9% at 30 days, 85.0%
t 6 months, and 61.0% at 12 months.
linical outcomes. OVERALL RESULTS. The 12-month rate
f MACE for all patients in the registry was 7.5% (95%
onfidence interval: 6.9% to 8.1%) (Table 3). Of note,
here were no cases of emergent cardiac bypass surgery.
mong patients receiving the Endeavor ZES plus a BMS
r another DES, the MACE rates were 12.7% and
0.7%, respectively. The 12-month overall incidence of
ll ARC-defined stent thrombosis was 1.8%. At 12
onths, the ARC definite and probable stent thrombosis
ate was 1.1%, and the per protocol stent thrombosis rate
as 1.0%. The ARC definite and probable late stent
Table 2. Lesion and Procedure Characteristics
Overall
n  8,314 Patients
n  10,339 Lesions
n
Total stent length (mm) 23.48 12.21
Vessel location
LAD 46.6 (4,817)
LCX 22 (2,274)
RCA 27.8 (2,877)
Left main 1.9 (196)
SVG 1.7 (175)
Lesion class
A 9 (928)
B1 30.8 (3,182)
B2 35 (3,623)
C 25.2 (2,606)
Reference vessel diameter, mm
2.5 9.7 (999)
2.5–3.0 63.7 (6,584)
3.0 26.7 (2,756)
Lesions treated 1.24 0.52
Stents implanted/patient 1.47 0.80
Lesion length, mm 18.5 10.6
Long lesions (20 mm) 30.4 (3,139)
Ratio stent/lesion length 1.36 0.69
Minimum stent diameters implanted, mm
2.5 28.6 (2,951)
2.5 71.4 (7,388)
Values are reported as mean SD or % (n).LAD left anterior descending coronary artery; LCX left circumflex artery; RCA right coronary arterhrombosis rate was 0.4%, and the per protocol late stent
hrombosis rate was 0.3%. Stent thrombosis rates were
.4% for patients receiving ZES and BMS and 1.8% for
hose receiving ZES with another DES. At 12 months,
he rate of TLR was 4.5%, nontarget lesion target vessel
evascularization (TVR) was 0.7%, TVR was 4.9%, and
arget vessel failure (TVF) was 7.2%.
ESULTS FOR PATIENTS WITH STANDARD- VERSUS
XTENDED-USE LESIONS AND CHARACTERISTICS. Clinical
utcomes at 12 months were compared between patients in the
tandard group and patients in the extended-use group (Figs. 2
o 4, Table 3). The 12-month rate of MACE was 4.3% for
atients in the standard group compared with a rate of 8.6%
p  0.001) for patients treated in the extended-use group.
here were 24 of 191 (1.2%) deaths in the standard group, of
hich 19 were attributed by the CEC to cardiac causes, and
67 of 6,189 (2.9%) deaths in the extended-use group, of
hich 116 were deemed cardiac death by the CEC. The
2-month incidence of ARC definite and probable stent
hrombosis was 0.4% in the standard group and 1.4% in the
xtended-use group (p  0.001) (Fig. 3). Compared with the
tandard group, the rates of TLR for the extended-use group
ere significantly higher (2.8% vs. 5.0%, p  0.001). Similar
ndard-Use
125 Patients
258 Lesions
Extended-Use
n  6,189 Patients
n  8,081 Lesions
p Value
(Standard- vs. Extended-Use)
08 7.55 24.43 13.06 0.001
.9 (1,127) 45.7 (3,690) 0.001
.3 (525) 21.6 (1,749) 0.108
.8 (606) 28.1 (2,271) 0.243
N/A 2.4 (196) —
N/A 2.2 (175) —
.5 (351) 7.1 (577) 0.001
.5 (938) 27.8 (2,244) 0.001
.2 (681) 36.4 (2,942) 0.001
.8 (288) 28.7 (2,318) 0.001
N/A 12.4 (999) —
.6 (1,707) 60.4 (4,877) 0.001
.4 (551) 27.3 (2,205) 0.006
06 0.26 1.31 0.58 0.001
13 0.39 1.59 0.87 0.001
32 5.54 19.40 11.48 0.001
.7 (422) 33.6 (2,717) 0.001
37 0.51 1.36 0.74 0.869
.2 (479) 30.6 (2,472) 0.001
.8 (1,779) 69.4 (5,609) 0.001Sta
 2,
n  2,
20.
49
23
26
15
41
30
12
75
24
1.
1.
15.
18
1.
21
78y; SVG saphenous vein graft.
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1232ifferences exist for the 12-month rates of TVR (3.0% vs.
.6%, p  0.001) and TVF (4.3% vs. 8.2%, p  0.001).
UBGROUP OUTCOMES. The rates of MACE, TLR, and
RC definite and probable stent thrombosis at 12 months
re reported for key subgroups in Table 4.
Table 3. 12-Month Clinical Outcomes for Overall Population and Patients W
Overall
(n  7,832)
Death (all) 2.4 (191)
Cardiac 1.7 (135)
MI (all) 1.6 (128)
Q-wave 0.4 (31)
Non–Q-wave 1.3 (98)
Death (cardiac)  MI (all) 3.0 (238)
ARC deﬁnite stent thrombosis 0.6 (49)
0–30 days 0.4 (28)
31–365 days 0.3 (23)
ARC deﬁnite  probable stent thrombosis 1.1 (88)
0–30 days 0.8 (59)
31–365 days 0.4 (31)
All ARC stent thrombosis 1.8 (144)
0–30 days 0.8 (59)
31–365 days 1.1 (89)
Per protocol stent thrombosis 1.0 (82)
0–30 days 0.8 (62)
31–365 days 0.3 (21)
TLR 4.5 (349)
TVR 4.9 (387)
TVR (nontarget lesion) 0.7 (52)
TVF 7.2 (565)
MACE 7.5 (587)
Values are % (n).
ARC  Academic Research Consortium; MACE  major adverse cardiac events; MI  myoca
revascularization.
Figure 2. Cumulative Incidence of MACE at 12 Months
Cumulative incidence curves of major adverse cardiac events (MACE) for
all patients and patients in the standard- and extended-use groups at
12 months.iscussion
his report describes 12-month data from the first large
rospective registry of the Endeavor ZES. These results,
tandard Versus Extended-Use Clinical and Lesion Characteristics
andard-Use
 2,125)
Extended-Use
(n  6,189)
p Value
(Standard- vs. Extended-Use)
1.2 (24) 2.9 (167) 0.001
0.9 (19) 2.0 (116) 0.001
0.7 (15) 1.9 (113) 0.001
0.2 (4) 0.5 (27) 0.147
0.5 (11) 1.5 (87) 0.001
1.5 (30) 1.6 (208) 0.001
0.1 (3) 0.8 (46) 0.001
0.1 (2) 0.4 (26) 0.028
0.0 (1) 0.4 (22) 0.015
0.4 (9) 1.4 (79) 0.001
0.4 (8) 0.9 (51) 0.035
0.0 (1) 0.5 (30) 0.002
0.8 (16) 2.2 (128) 0.001
0.4 (8) 0.9 (51) 0.035
0.4 (9) 1.4 (80) 0.001
0.4 (9) 1.3 (73) 0.001
0.4 (8) 0.9 (54) 0.019
0.0 (1) 0.3 (20) 0.024
2.8 (56) 5.0 (293) 0.001
3.0 (61) 5.6 (326) 0.001
0.3 (6) 0.8 (46) 0.017
4.3 (87) 8.2 (478) 0.001
4.3 (87) 8.6 (500) 0.001
arction; TLR  target lesion revascularization; TVF  target vessel failure; TVR  target vessel
Figure 3. Cumulative Incidence of ARC Definite And Probable Stent
Thrombosis at 12 Months
Cumulative incidence curves of Academic Research Consortium (ARC) deﬁ-
nite and probable stent thrombosis for all patients and patients in theith S
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(n
rdial infstandard- and extended-use groups at 12 months.
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1233btained from 188 treatment centers, provide compelling
vidence for the safe and effective use of the Endeavor ZES
n routine clinical practice. The results are similar to those
eported in randomized clinical trials, despite the high
roportion of patients with high-risk characteristics and
omplex lesions that are usually excluded from randomized
rials.
Outcome data were available for 7,832 of 8,314 patients,
hich represents a 94.2% 1-year follow-up rate. The low
umber of patients lost to follow-up compares favorably
ith other published registries (88% to 95%) (14–16) and
urther strengthens the validity of the data reported. Addi-
ionally, all events related to end points were adjudicated by
n independent CEC, and although there was no manda-
ory angiographic follow-up, if a patient underwent
ngiography-related revascularization, the angiogram was
vailable for adjudication of the event by the committee. All
eported events were adjudicated—unique to registry stud-
es—supporting the high quality of the registry. Addition-
lly, the database was queried for possible events not
eported to assure accuracy of the data. Random monitoring
f 10% of patients was performed to detect and correct any
naccuracies in the registry data and to check for underre-
orting of events.
The overall 12-month MACE rate was 7.5%. The rate
as 4.3% in the standard group, which was more represen-
ative of those enrolled in randomized trials (4,7–11), and
.6% in the extended-use group. It is important to note that
n the E-Five registry the MACE definition included
mergent cardiac bypass surgery, which was not included in
efinitions used by other DES registries (e-Cypher,
TENT [Strategic Transcatheter Evaluation of New Ther-
pies] REWARDS [Cypher Registry Experience at the
ashington Hospital Center With Drug-Eluting Stents],
RRIVE [The TAXUS Peri-Approval Registry: A Multi-
enter Safety Surveillance]) (14–17). Overall outcomes
eported for the sirolimus-eluting stent (SES) and
aclitaxel-eluting stent (PES) in recent registry reports
uggest that the Endeavor ZES performs similarly to other
ES (14–17). The overall rate of MACE at 12 months was
eported to be 5.8% for the SES in the e-Cypher registry
Table 4. MACE and ARC Definite and Probable Stent
Diabetes
(n  2,563)
Lesio
(n
MACE 9.7 (248)
TLR 5.3 (136)
ARC deﬁnite/probable 1.5 (39)
0–30 days 1.1 (29)
31–365 days 0.4 (11)
Values are % (n). *At least 2 lesions in different vessels.
Abbreviations as in Table 3.13) and at 9 months was 8.0% and 7.5% for the SES andES groups, respectively, in the STENT registry report
15). The REWARDS registry, which compared outcomes
ith everolimus-eluting stent and PES placement in over
,700 consecutive patients treated at a single site, reported
o difference in the rate of MACE at 12 months (hazard
atio: 1.06, 95% confidence interval: 0.85 to 1.33), although
ctual rates were not reported (16).
tent thrombosis. Events were adjudicated, unlike other
tent registries, to confirm the per protocol and ARC-
efined stent thrombosis outcomes. The incidence of ARC
efinite and probable stent thrombosis was 1.1% overall,
ith 0.8% occurring early (0 to 30 days) and 0.4% occurring
ate (31 to 365 days) (Table 3). This value is consistent with
he pooled analysis from 6 clinical trials of Endeavor DES
n  2,132), which revealed an ARC definite and probable
tent thrombosis rate of 0.7% among patients without
omplex indications (18). The per protocol stent thrombosis
ates for the Endeavor ZES were 1.0% overall, 0.8% early,
nd 0.3% late, which are similar to the cumulative 12-
onth data from the e-Cypher registry, which reported a
.87% incidence of per protocol stent thrombosis overall
ith a rate of late stent thrombosis of 0.19% (14). However,
Figure 4. Cumulative Incidence of TLR at 12 Months
Cumulative incidence curves of target lesion revascularization (TLR) for
all patients and patients in the standard- and extended-use groups at
bosis Rates for Key Subgroups at 12 Months
0 mm
68)
Lesions <3.0 mm
(n  3,408)
Multivessel*
(n  854)
1) 8.6 (277) 9.8 (84)
8) 5.4 (173) 6.2 (53)
) 1.5 (49) 1.9 (19)
) 1.1 (35) 1.4 (12)
) 0.5 (16) 0.5 (4)Throm
ns >2
 2,6
9.8 (26
5.5 (14
1.5 (41
1.1 (29
0.4 (1212 months.
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1234he e-Cypher registry used a more restrictive definition of
tent thrombosis, requiring angiography or autopsy for
efinite stent thrombosis and target vessel-related MI or
ardiac death for likely stent thrombosis occurring within 30
ays of the index procedure. The proportion of patients with
ES-related thrombosis who were being treated with dual
ntiplatelet therapy was 84.1% in eCypher, and 71.5% of
atients in ARRIVE with PES thrombosis were receiving
ual antiplatelet therapy at 12 months (16,17). Patients
eceiving the Endeavor ZES experienced a low rate of stent
hrombosis, despite a comparatively low 12-month rate
61.0%) of dual antiplatelet therapy.
As expected, the rates of ARC definite and probable stent
hrombosis are greater among patients in the extended-use
roup compared with the standard group (1.4% vs. 0.4%,
djusted p  0.001). These rates are lower than those
eported for PES in the ARRIVE registry, although the
atient groups are defined in the same way (1.8% and 0.9%
or extended-use and standard-use groups, respectively).
dentified factors that might impact the incidence of stent
hrombosis include the duration of antiplatelet therapy, the
resence of diabetes or acute coronary syndrome, renal
ailure, low ejection fraction, and bifurcation lesions (19,20),
nd the ability to compare outcomes across nonrandomized
tudies is limited by selection bias.
tudy limitations. An important limitation of this study is
he potential for underreporting of adverse events. Several
easures, including ongoing random monitoring of 10% of
atients enrolled and adjudication of events by review of
lectrocardiogram and laboratory values for MI and angio-
raphy for stent thrombosis and revascularization, were
mployed to minimize this occurrence in E-Five, but the
nherent possibility exists for inaccuracy of reported
utcomes.
Another limitation of this study is the subjective nature of
he lesion length data, which were reported by visual
stimation or by local quantitative angiographic methods,
ut were not collected in a core laboratory.
The importance of adequate antiplatelet therapy during
nd after stent placement has been highlighted in a number
f recent publications and is an element that can be highly
ariable in real-world patient populations. Premature dis-
ontinuation of antiplatelet agents has been shown to
ncrease the incidence of stent thrombosis (21,22). In this
egistry, 85.0% of patients at 6 months and 61.0% at 12
onths were taking dual antiplatelet therapy. It is unclear
ow long dual antiplatelet therapy should be continued,
ecause late stent thrombosis is reported well beyond 12
onths (2,16,19,23,24). Longer follow-up of patients re-
eiving the Endeavor ZES will be necessary to confirm the
xtended long-term safety of this DES and is being under-
aken in a subset of approximately 2,000 patients from this
tudy cohort.onclusions
id-term results from the E-Five registry suggest that
eal-world outcomes among over 8,000 consecutive patients
ith both simple and extended-use characteristics and
esions are comparable to those of the pooled Endeavor
linical trials. The 12-month rate of MACE was compara-
le to rates reported across other registry trials, and safety
utcomes as measured by rates of cardiac death, MI, and
tent thrombosis were low, despite the high proportion of
atients in the extended-use population. These 12-month
esults clearly provide evidence for safety and effectiveness of
he Endeavor ZES in real-world patients and are consistent
ith those reported in the ENDEAVOR trials.
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APPENDIX
or a complete list of the E-Five Investigators and institutions, please see
he online version of this article.
